07/23/2026
For those of you thinking about getting the mFlusiva mRNA flu vaccine, PLEASE READ!!!!
ICAN recently sent an urgent letter to FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) before its last meeting, documenting alarming safety and efficacy failures with Moderna’s new mRNA flu vaccine, mFlusiva.
Shockingly, the committee voted unanimously to recommend mFlusiva anyway. It now goes to FDA Acting Commissioner Kyle Diamantas for official approval.
ICAN raised several concerns with mFlusiva, including…
Unfavorable Benefit-Risk Ratio: mFlusiva’s trial claimed it reduced absolute influenza risk by a mere 0.8%, while a staggering 6.4% of recipients suffered severe reactions—five times the rate of the standard flu shot.
Concerning Pattern of Deaths: Five mFlusiva recipients died in Part A of the Phase 3 immunogenicity trial, compared to just one in the group that got the standard flu shot.
Cardiac Risk: Cardiac events—including fatal cardiac arrest and congestive cardiac failure—occurred during the trials, echoing the well-documented cardiac dangers of mRNA technology learned with Covid vaccines.
The most infuriating part of the VRBPAC meeting was that the members actually acknowledged and discussed some of these concerns, but instead of postponing its recommendation, the committee simply recommended that further studies be done after mFlusiva’s approval. Meaning, America’s most vulnerable seniors will once again be used as guinea pigs while the FDA takes years to figure out if the vaccine is actually harming people.
